Filters: Filter is   [Clear All Filters]
56 Dean Street. ChemSex and hepatitis C: A guide for healthcare providers | HCV Action. 56 Dean Street; 2014 .
AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;(62):932-954.
AASLD-IDSA . Recommendations for testing, managing, and treating hepatitis C [Internet]. 2017.
AbbVie Inc.VIEKIRA XR (dasabuvir, ombitasvir, paritaprevir, and ritonavir) [Package insert]. North Chicago: AbbVie Inc.; 2017.
Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(1):1-10.
Abergel A, Asselah T, Metivier S, Loustaud-Ratti V, Loustaud-Ratti V. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis. 2016;16(4):459-464.
Afdhal NH, Bacon BR, Patel K, Lawitz EJ, Gordon SC, Nelson DR, et al. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin. Gastroenterol. Hepatol. 2015;13(4):772-779.
Afdhal NH, Zeuzem S, Kwo PY, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-1898.
Afdhal NH, Reddy KR, Nelson DR, Lawitz EJ, Gordon SC, Schiff ER, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-1493.
Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327(21):1490-1495.
Akiyama MJ, Kaba F, Rosner Z, Alper H, Holzman RS, MacDonald R. Hepatitis C Screening of the "Birth Cohort" (Born 1945-1965) and Younger Inmates of New York City Jails. American Journal of Public Health. 2016;106(7):1276-1277.
Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Annals of Internal Medicine. 2003;138(3):187-190.
Allison RD, Tong X, Moorman AC, Ly KN, Rupp L, Xu F, et al. Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010. J Hepatol. 2015;63(4):822-828.
Alonso S, Riveiro-Barciela M, Fernández I, Rincón D, Real Y, Llerena S, et al.. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. Journal of Viral Hepatitis. 2017;24(4):304 - 311.
Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003;52(RR-3):1-13, 15.
Alvarez D, Dieterich D, Brau N, Moores L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat. 2006;13:683-689.
Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, Latka MH, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis. 2008;46(12):1852-1858.
Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359-365.
Apers L, Berghe WVanden, De Wit S, Kabeya K, Callens S, Buyze J, et al. Risk Factors for HCV Acquisition Among HIV-Positive MSM in Belgium:. Journal of Acquired Immune Deficiency Syndromes. 2015;68(5):585 - 593.
Arai Y, Noda K, Enomoto N, Arai K, Yamada Y, Suzuki K, et al. A prospective study of hepatitis C virus infection after needlestick accidents. Liver. 1996;16(5):331-334.
Modify or remove your filters and try again.